Aldeyra (ALDX) announced that the FDA has granted fast track designation for ADX-2191 for the treatment of retinitis pigmentosa. There is currently no approved treatment for patients with most forms of retinitis pigmentosa, a clinical group of rare genetic eye diseases characterized by retinal cell death and loss of vision. Retinitis pigmentosa affects more than one million people worldwide.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALDX:
- Aldeyra Therapeutics: Positive NDA Resubmission and Strategic Advancements Support Buy Rating
- Buy Rating for Aldeyra Therapeutics Driven by FDA Progress and Strategic Partnership Potential
- Aldeyra receives orphan designation for ADX-2191 from EMA
- FDA Accepts Aldeyra’s Reproxalap Application for Review
- Aldeyra announces FDA acceptance for review of reproxalap NDA